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Abstract
Purpose Colitis is a common and serious complication of chronic granulomatous disorder (CGD) and requires assessment.
Colonoscopy is invasive and carries risks of serious complication. We therefore assessed non-invasive monitoring via magnetic
resonance imaging (MRI). We also evaluated fecal calprotectin (FCP), the Harvey-Bradshaw index (HBI) clinical score, and
serum cytokines.
Methods We recruited 10 patients with CGD (8 males, mean age 29.6 years), scored a modified HBI, and obtained stool for FCP.
The following day we took blood for cytokine measurement via Luminex, performed MR enterography (scored by two inde-
pendent radiologists using three systems: London score, CDMI, and MaRIA) followed by colonoscopy with disease activity
measurement via ulcerative colitis endoscopic index of severity (UCEIS).We assessed patient experience after each investigation
and overall preference with follow-up questionnaires.
Results MRI scores correlated well with colonoscopic gold standard (for London score R2 0.91, p < 0.0001; for CDMI R2 0.83,
p = 0.0006; for MaRIA R2 0.89, p = 0.0002). MRI was better tolerated and generally preferred, quicker, and visualized the entire
large bowel whereas colonoscopy did not reach the terminal ileum in 3 participants. Elevated FCP accurately differentiated
patients with colitis from those without, and log(calprotectin) correlated well with disease activity (R2 0.71, p = 0.009). Serum
interleukin (IL)-12 concentration correlated with colitis activity but IL-1β and TNF did not. Harvey-Bradshaw index did not
correlate with colitis activity.
Conclusions MRI and fecal calprotectin are useful methods for monitoring CGD colitis and should reduce the need for colonos-
copy in these patients. IL-12 may represent an appropriate target for treatment.
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Introduction
Chronic granulomatous disorder (CGD) is a primary im-
munodeficiency caused by mutations in the nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase en-
zyme complex [1]. Affected individuals suffer recurrent
infection with bacterial and fungal pathogens but also
develop inflammatory complications, most notably a co-
litis [2]. CGD-associated colitis is distinct from other
inflammatory bowel diseases: the distribution of disease
often resembles ulcerative colitis [3] but histologically
more resembles Crohn’s disease [4], characterized by
granulomas and cryptitis. Colitis contributes a signifi-
cant burden of morbidity in CGD, and treatment can
be complex [5].
As with other forms of inflammatory bowel disease
(IBD), it is important to monitor the activity of CGD-
associated colitis. This is traditionally undertaken by colo-
noscopy, which is an invasive procedure carrying a risk of
perforation and hemorrhage [6]. Furthermore, histological
appearances tend to be consistent between patients and do
not necessarily inform management; thus, the utility of
obtaining biopsies is limited.
More recently, MRI has been shown to be accurate in the
diagnosis and monitoring of inflammatory bowel diseases
[7–9]. This imaging modality is considered safe and does
not involve ionizing radiation. We sought to ascertain whether
MRI could accurately assess the colonic appearance in CGD,
compared with colonoscopy as a gold standard. We also in-
vestigated other non-invasive monitoring techniques. The fe-
cal calprotectin (FCP) level, now well established in other
IBD, has recently been suggested to be useful in pediatric
CGD-associated colitis [10]. We also assessed a clinical score
based on the Harvey-Bradshaw index (HBI) used for Crohn’s
disease [11] and blood levels of inflammatory cytokines other
than C-reactive protein, focusing on molecules which have
pharmacological inhibitors available.
Materials and Methods
Recruitment and Ethics
Adult patients (≥ 18 years) with a confirmed diagnosis of
CGD were recruited from the national CGD clinic at the
Royal Free Hospital, London, or via the UK national CGD
specialist nurse. Inclusion and exclusion criteria are listed
in Supplementary Table 1. We estimated approximately 30
patients were eligible nationally and recruited 10. The
study was approved by the NHS Research Ethics
Committee (REC 15/LO/1334) and all participants provid-
ed written informed consent.
Study Design
Patients were clinically assessed, with calculation of a modi-
fied Harvey-Bradshaw index (see below), within 1 week of
the investigations. A day before the procedures, patients took
standard bowel cleansing with Moviprep® (polyethylene gly-
col). They were provided with containers to collect stool sam-
ples for fecal calprotectin (before commencingMoviprep) and
investigation of infection (see below) which they brought to
hospital on the day of the procedures.
On the day of the investigations, blood was collected for
measurement of C-reactive protein and serum cytokines; pa-
tients drank up to 2 l of 2%mannitol solution asMRI contrast,
the first half between 2.5 and 1.5 h before the scan time (in
order to reach the colon) and the second half over the last hour
before the scan time (to distend the small bowel). The actual
volume ingested was occasionally adjusted according to pa-
tient tolerance. Patients then underwent MRI scanning and
10 min afterwards were given a questionnaire regarding toler-
ability (see Supplementary Appendix 1). They subsequently
underwent colonoscopy and after recovery from sedationwere
given a similar questionnaire pertaining to their experience of
colonoscopy (see Supplementary Appendix 2). When fully
recovered, patients returned home. One week later, they were
sent a follow-up questionnaire regarding tolerability and pref-
erences (see Supplementary Appendix 3).
MRI Scanning and Scoring Systems
MRI was performed on a Philips (Philips Medical Systems,
Eindhoven, Netherlands) 1.5T Ingenia or 1.5T Nova Dual
scanner. Table 1 summarizes the sequence of MRI images
and adjunctive medications administered. Scoring of MRI im-
ages was performed independently by two specialist radiolo-
gists with 12 and 17 years of experience in enteric MRI, re-
spectively, blinded to colonoscopy findings. Three validated
Table 1 Summary of MRI sequences and adjunctive medications used
in the study
20 mg intravenous hyoscine butylbromide (unless contraindicated)
MRI sequences (Philips 1.5T with body coil):
5 mm coronal and axial SSH-TSE (HASTE)
5 mm coronal and axial BFFE (Tru-FISP)
2.5 mm coronal dynamic pre- and post-contrast (intravenous gadolini-
um chelate 0.2 mg/kg) THRIVE (VIBE)
2.5 mm axial delayed post-contrast THRIVE (VIBE)
6 mm axial diffusion (0, 50, 600) with ADC map
SSH single shot, TSE turbo spin echo, HASTE half-Fourier-acquired
single-shot turbo spin echo, BFFE balanced fast field echo, FISP fast
imaging with steady state precession, THRIVE T1 high-resolution isotro-
pic volume excitation, VIBE volumetric interpolated breath-hold exami-
nation, ADC apparent diffusion coefficient
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MRI activity scores were calculated (see Supplementary
Appendix 4 for further details):
– The BLondon^ score [12], calculated as 1.79 + 1.34 ×mu-
ral thickness + 0.94 ×mural T2 signal
– The Crohn’s disease MRI index (CDMI) score [12], cal-
culated as mural thickness + mural T2 signal + enhance-
ment + perimural T2 signal
– The magnetic resonance index of activity (MaRIA) score
[13], calculated as 1.5 × wall thickness (mm) + 0.02 × rel-
ative contrast enhancement + 5 × edema + 10 × ulceration
Scoring was performed on each bowel segment (rectum,
sigmoid, splenic flexure, transverse colon, hepatic flexure,
caecum, and terminal ileum) and is presented as the average
from the two radiologists. A total score and a Bcolon-only^
score (without the terminal ileum) was then calculated for
each scoring system.
Colonoscopy and Scoring System
A standard colonoscopy was performed as far as the terminal
ileum (if possible) with sedation and analgesia as required.
The severity of colitis was scored as consensus between two
endoscopists for each bowel segment (rectum, sigmoid, splen-
ic flexure, transverse colon, hepatic flexure, caecum, and ter-
minal ileum) using the ulcerative colitis endoscopic index of
severity (UCEIS) system [14]. This validated system assesses
the vascular pattern, evidence of bleeding, erosions, and ul-
cers. A total score and a Bcolon-only^ score (without terminal
ileum) were then calculated. Biopsies were taken from each
bowel segment for histopathological assessment, except the
transverse colon. From the histological patterns observed,
we classified biopsies as Bnormal^ (the presence of pigmented
macrophages was permitted), demonstrating acute changes of
colitis (cryptitis, crypt abscesses, inflammatory cell infiltrate,
and ulceration) or demonstrating chronic quiescent changes
only (crypt architectural distortion or granulomas without
inflammation).
Modified Harvey-Bradshaw Index and Patient
Questionnaires
The Harvey-Bradshaw index is a clinical index which is
used in Crohn’s disease patients to define disease activity
[11]. Lacking a specific clinical index for CGD, we utilized
the Harvey-Bradshaw score because of similar histology
and often similar symptoms to Crohn’s disease. However,
we slightly modified the list of complications as CGD pa-
tients would not be expected to suffer some conditions
specific to Crohn’s. The modified Harvey-Bradshaw scor-
ing is summarized in Table 2.
Measurement of Serum C-Reactive Protein, Cytokines,
and Markers of Immune Activation
C-reactive protein was measured in patient serum via nephe-
lometry in the hospital diagnostic laboratory. Cytokines (in-
terleukin (IL)-1β, IL-6, IL-12, and tumor necrosis factor
(TNF)), markers of immune activation (soluble cluster of dif-
ferentiation 14 (sCD14)), and endothelial activation (intercel-
lular adhesion molecule-1 (ICAM-1)) were measured via
Luminex technology at the Multiplex Core Laboratory,
UMC Utrecht, Netherlands. We assigned a value of zero to
any undetectable results.
Measurement of Fecal Calprotectin and Tests for Stool
Pathogens
Fecal calprotectin was measured via enzyme immunoassay in
the diagnostic laboratory. To exclude infection, diagnostic lab-
oratories performed polymerase chain reaction (PCR) for vi-
ruses (adenovirus, norovirus, enterovirus, rotavirus, and
sapovirus) and bacteria (Campylobacter, Salmonella,
Shigella, Escherichia coli O157). Clostridium difficile was
screened via the glutamate dehydrogenase (GDH) detection
test with subsequent testing for toxin and toxin gene if re-
quired. Microscopy was performed to exclude helminths or
protozoa (including ova and cysts).
Results
Patient Characteristics
Table 3 details the patient characteristics. Of the 10 patients
recruited, seven had X-linked CGD (gp91phox) and there was
Table 2 Modified Harvey-Bradshaw index
Parameter Scoring
General well-being 0 = very well
1 = slightly below average
2 = poor
3 = very poor
4 = terrible
Abdominal pain 0 = none
1 =mild
2 =moderate
3 = severe
Liquid stools Number of liquid stools per day
Abdominal mass 0 = none
1 = dubious
2 = definite
3 = tender
Complications 1 point for each: anal fissure,
active fistulae, abscess
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one patient each with p40phox, p47phox, and p67phox autosomal
recessive CGD. Eight patients were male and the mean age
was 29.6 years. All patients were receiving antibiotics and
antifungal prophylaxis; four patients were on significant im-
munosuppression and one further patient was taking
mesalazine. Seven patients had a known history of colitis prior
to the investigations, and the majority of patients had previ-
ously undergone both MRI and colonoscopy.
All tests for gastrointestinal infection were negative.
Further scores and measurements generated in the study are
detailed in Supplementary Table S2. Clinical features of in-
flammatory bowel disease, defined by the Harvey-Bradshaw
parameters, are presented in Supplementary Table S3, and
detailed endoscopic findings are included in Supplementary
Table S4.
Completion Rates and Adverse Events in MRI
and Colonoscopy
MRI scans were completed successfully in all partici-
pants, with no significant adverse events attributed to
MRI. The mean (± SD) time recorded for MRI was
27.6 ± 6.6 min. Colonoscopy reached the terminal ileum
in seven, caecum in two, and splenic flexure in one
patient. All patients received intravenous sedation ex-
cept one who only received inhaled nitrous oxide
(Entonox®). The mean (± SD) time recorded for colo-
noscopy, regardless of whether the terminal ileum was
reached, was 35.7 ± 14.6 min. One participant was brief-
ly hospitalized due to fever, abdominal pain, and rigors
on the night after the procedures. No organisms were
identified in blood cultures, and the episode was con-
sidered to possibly relate to translocation of bacterial
products during colonoscopy.
MRI and Colonoscopy Scores of Colitis Activity
Correlate Well
As colonoscopy did not reach the terminal ileum in three
patients, we used total UCEIS score and total MRI scores as
far as the caecum (n = 9) for study outcomes. Overall correla-
tion between the two radiologists was good (R2 0.90 for the
London score, 0.88 for CDMI, and 0.82 for MaRIA). Results
from all scoring systems indicated maximal colitis in the distal
colon (Supplementary Fig. 1).
As detailed in Fig. 1, there was a strong correlation between
UCEIS and each of theMRI scores (for London score R2 0.91,
p < 0.0001; for CDMI R2 0.83, p = 0.0006; for MaRIA R2
0.89, p = 0.0002). Significant correlations persisted when
analysis was restricted only to patients with macroscopic co-
litis (n = 6; for London score R2 0.80, p = 0.02; for CDMI R2
0.66, p = 0.05; for MaRIA R2 0.75, p = 0.03).Ta
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We also analyzed correlation between UCEIS and the MRI
scores for each bowel segment, as detailed in Table 4. There
was a significant correlation for each segment. However, MRI
suggested presence of inflammation in the rectum in three out
of four patients where colonoscopy was normal. In two of
these cases, the MRI was reported as abnormal by only one
radiologist and suggested mild disease. However, in one pa-
tient, the MRI report from both radiologists was compatible
with significant colitis: this patient had previously received
treatment for anal cancer and perianal fistulae. In total, five
patients had clinical evidence of active perianal disease, and
MRI appeared to overinterpret rectal findings compared with
colonoscopy in two of these.
In one patient’s MRI, one radiologist’s interpretation sug-
gested presence of disease in the transverse colon even though
colonoscopy was normal: this patient did have severe macro-
scopic colitis as far as the splenic flexure and this may there-
fore represent difference between modalities or investigators
in identifying the transition point. There were also six bowel
segments across the study (out of 64 examined by colonosco-
py) where MRI failed to identify macroscopic colitis: half of
these were in the caecum while none were in the sigmoid or
rectum. None of these discordant segments had severe colitis
(maximal UCEIS score 4). In all segments where there was
discordance and available biopsies, histology supported the
colonoscopy findings.
Tolerability and Patient Preferences for MRI Versus
Colonoscopy
When asked about the least acceptable and overall worst parts
of the procedures (Table 5), participants identified different
aspects of MRI including bowel preparation, breath holds,
noise, and various forms of pain or discomfort. For colonos-
copy, there was near-unanimous reporting that bowel prepa-
ration was the least acceptable, and this was also stated by 3
patients as the Boverall worst^ aspect; discomfort was the
other major feature.
When asked specific questions relating to the tests (Fig. 2
and Supplementary Fig. 2), there tended to be a preference for
MRI over colonoscopy in most areas. The difference in scores
was statistically significant for the acceptability of taste of the
bowel preparation (score ± SD for MRI 6.1 ± 1.1, for colonos-
copy 3.8 ± 2.6, p = 0.02), preference for being less awake
(score ± SD for MRI 5.4 ± 1.3, for colonoscopy 3.4 ± 2.3,
p = 0.03), and most notably for pain (score ± SD for MRI
6.8 ± 0.6, for colonoscopy 4.3 ± 1.7, p = 0.0004).
Colonoscopy only scored (non-significantly) higher than
MRI for three questions relating to feeling confused, puzzled,
and understanding what was happening (Fig. 2).
We received follow-up questionnaires from nine patients,
and results are summarized in Fig. 3. Again, there was an
overall preference for MRI over colonoscopy. When asked
Fig. 1 Correlations between endoscopic and MRI scores. a–c
Correlations between the endoscopic UCEIS score and the MRI scoring
systems, MaRIA score (a), London score (b), and CDMI score (c).
Analysis is based on the total scores for the entire colon (rectum to
caecum) and p values are derived from Pearson correlation
Table 4 Correlation of UCEIS
scores with each of the MRI
scores according to bowel
segment
Bowel segment n MaRIA score London score CDMI score
R2 p value R2 p value R2 p value
Rectum 10 0.51 0.02 0.62 0.007 0.68 0.003
Sigmoid 10 0.82 0.0003 0.82 0.0003 0.84 0.0002
Descending colon/splenic flexure 10 0.88 < 0.0001 0.74 0.001 0.77 0.0009
Transverse colon 9 0.52 0.03 0.65 0.009 0.62 0.01
Hepatic flexure/ascending colon 9 0.89 0.0002 0.84 0.0005 0.83 0.0006
Caecum 9 0.64 0.01 0.56 0.02 0.56 0.02
Terminal ileum 7 0.996 < 0.0001 1 N/A 1 N/A
N/A not applicable
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to rank the various elements of the tests, bowel preparation for
the colonoscopy was universally ranked as the worst element.
When asked to choose one modality, assuming that a test was
essential and that the tests were equivalent in terms of diag-
nosis and safety, six preferred MRI and three opted for
colonoscopy.
Additional Information Obtained from Each Modality
and Correlation with Histological Findings
MRI additionally identified an undescended testis in one indi-
vidual. Histopathological examination of biopsies obtained
during colonoscopy (Supplementary Table S5) from patients
with colitis revealed evidence of crypt architectural distortion,
cryptitis, and occasionally crypt abscesses or ulcers. Most pa-
tients with colitis had evidence of diffuse inflammatory cell
infiltrate (acute in patient 1). Pigmented macrophages were
common. Where sampled, the terminal ileum was normal ex-
cept for one patient with pigmented macrophages and one
with granulomas. In total, granulomas were seen in four pa-
tients, including one without active colitis. Another patient
without active colitis had evidence of mild crypt architectural
distortion: he was already on mesalazine for a prior history of
inflammatory bowel disease.
Overall, there were six bowel segments where both colo-
noscopy and MRI identified the bowel as normal, but some
chronic or quiescent histological changes were noted on biop-
sy. There were also a further two segments (both in a single
patient with definite colitis noted elsewhere in the bowel)
where acute histological changes were noted despite normal
UCEIS and MRI scores. Conversely, there were four bowel
segments where all modalities identified the bowel as colitic,
but histology was normal, plus another one segment where
only chronic, quiescent histological changes were seen despite
abnormal colonoscopy and MRI.
Table 5 Least acceptable and overall worst part of both investigations
according to participant experience questionnaires (numbers represent
how many participants provided that particular answer)
MRI (n) Colonoscopy (n)
Least acceptable
Bowel preparation 4 9
Bowel test 1 0
Other Back pain
Lying on stomach
BNothing^
Pain
No entry 2 0
Overall worst part (free text answer)
Bowel preparation 1 3
Breath holds 3 N/A
Noise 2 N/A
Discomfort 0 3
Other Arm uncomfortable
Needing to go to the toilet
BNothing^
No entry 2 3
MRI magnetic resonance imaging, N/A not applicable
Fig. 2 Patient experience questionnaire outcomes. a–eResults (mean and
standard deviation) obtained from patient experience questionnaires for
questions common to both investigations. Scores for MRI are represented
in red and for colonoscopy in green. The range of scores for each question
was from 1 to 7
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Fecal Calprotectin Accurately Discriminates Patients
with and without Active CGD-Associated Colitis
and Demonstrates Better Correlation with Disease
Activity than Serum C-Reactive Protein
Fecal calprotectin levels were available from nine participants
(in one case, the sample provided was insufficient for analy-
sis). FCP levels elevated above the normal range (> 150 μg/g)
were able to accurately differentiate patients with colitis from
those without as assessed by total UCEIS (n = 8 with both a
calprotectin level and a total UCEIS); see Fig. 4a. This equates
to 100% sensitivity and 100% specificity in this small cohort.
In the patient without a total UCEIS score due to incomplete
colonoscopy, there was no colitis seen as far as the splenic
flexure (or proximal to this point by MRI) and a normal
calprotectin, consistent with other participants’ results.
Similarly, the patient with insufficient sample did have
endoscopic evidence of colitis (total UCEIS 12), and a subse-
quent calprotectin level was elevated at 528. There was a
significant correlation between UCEIS and log(calprotectin)
(R2 0.71, p = 0.009; Fig. 4e), but not between UCEIS and CRP
(R2 0.41, p = 0.06) or log(CRP) (R2 0.42, p = 0.06).
There were also significant differences in MRI scores
between patients with elevated or normal FCP (Fig. 4b–d).
The discrimination was not perfect due to elevated MRI
scores in the patient with abnormal radiological appear-
ances of the rectum not due to active colitis, as described
above. However, correlation between MRI scores and
log(calprotectin) was strong (for MaRIA R2 0.83, p =
0.0007; for London score R2 0.84, p = 0.0005; for CDMI
R2 0.87, p = 0.0003; Fig. 4f–h). The correlations of MRI
scores with log(calprotectin) were notably stronger than
those with CRP (for MaRIA R2 0.50, p = 0.02; for CDMI
R2 0.53, p = 0.02; for London score R2 0.50, p = 0.02) or
with log(CRP) (for MaRIA R2 0.44, p = 0.04; for CDMI
R2 0.43, p = 0.04; for London score R2 0.41, p = 0.05). The
patient with insufficient sample but subsequent elevated
calprotectin level had radiological evidence of colitis by
all scoring systems.
All participants with elevated FCP had evidence of acute
colitis on biopsies, whereas participants with normal FCP had
either normal histology or only chronic, quiescent changes.
The Harvey-Bradshaw Index Does Not Correlate Well
with CGD-Associated Colitis Disease Activity
Harvey-Bradshaw index did not differentiate well between
patients with and without active colitis as assessed by total
UCEIS score or elevated fecal calprotectin (p = 0.30), and
there was no significant correlation between Harvey-
Bradshaw index and total UCEIS score, fecal calprotectin,
any of the MRI scores, or CRP.
Interleukin 12May Be a Useful Indicator of CGD Colitis
Activity
Additional serum samples were available for 9 patients (in-
cluding all patients with evidence of colitis) in which we mea-
sured serum cytokines and markers of immune activation.
There were no consistently significant correlations between
total UCEIS or MRI scores with IL-1β, TNF, or sCD14.
There was a positive correlation between serum IL-6 concen-
tration and the UCEIS score (R2 0.67, p = 0.01) but not the
MRI scores. This discrepancy was attributable to the patient
with missing total UCEIS score due to incomplete colonosco-
py who had a very elevated level of IL-6 and other innate
cytokines despite no evidence of colitis: excluding this patient
from correlation analysis with MRI scores resulted in signifi-
cant (p < 0.05) results for all scores.
Fig. 3 Follow-up questionnaire outcomes. a Results (mean and standard
deviation) obtained from follow-up questionnaires. Scores for MRI are
represented in red and for colonoscopy in green. Participants were asked
to evaluate using a 7-point scale (1 =worst, 7 = best) for each investiga-
tion overall and for the component parts (bowel preparation and the test
itself). b Mean and standard deviation of ranks awarded to each of the
MRI drink, MRI scan, colonoscopy bowel preparation, and colonoscopy
itself on the follow-up questionnaire, starting (i.e., rank = 1) with the
worst aspect
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Serum IL-12 concentration correlated positively with
UCEIS score (R2 0.65, p = 0.02), MaRIA score (R2 0.47,
p = 0.04), and London score (R2 0.49, p = 0.04), as shown in
Fig. 5a–c; concentrations appeared to be consistently low in
patients without colitis (Fig. 5d), including in the patient with
high innate cytokine levels.
Interestingly, there were significant (p < 0.05) negative cor-
relations between serum-soluble ICAM-1 levels with each of
the MRI scores. This appears to be explained by the impact of
immunosuppression (corticosteroids or azathioprine) which
significantly lowered ICAM-1 levels regardless of the pres-
ence of severity of colitis (476,865 ± 126,033 pg/ml in pa-
tients on immunosuppression versus 805,914 ± 191,230 pg/
ml in other patients, p = 0.02; Fig. 5e). There were no similar
differences in relation to immune suppression for the other
serum proteins measured.
Discussion
We have here demonstrated the importance of non-invasive
techniques for diagnosis and monitoring of CGD-associated
colitis. MRI assessment of disease activity and log-
transformed fecal calprotectin correlated very well with the
endoscopic gold standard, while calprotectin could accurately
discriminate those with colitis from those without. Serum IL-
12 concentration may also be a useful correlate of disease
activity and point towards a target for treatment.
Colitis in CGD is important to diagnose and monitor.
Although CGD is considered an immune deficiency, severe
infectious complications are relatively rare, occurring every
few years in patients compliant with prophylactic antimicro-
bials [15, 16]. In contrast, colitis contributes considerably to a
daily symptom burden of living with CGD. Untreated, it can
lead to perforation, stricture formation, abscesses, fistulae, and
systemic effects including anemia and fatigue [3, 17]. The
long-term sequelae, including development of malignancy or
systemic complications of chronic inflammation, are not well
defined in CGD. However, data from other diseases suggests
these are likely to be significant [18]. Colitis activity directs
treatment, which is important to titrate so that iatrogenic im-
munosuppression is kept to a minimum; it is also a major
consideration in hematopoietic stem cell transplant decisions
and should be well controlled in the peritransplant period.
Colitis has traditionally been assessed via colonoscopy, and
this is still considered the gold standard. However, this inves-
tigation is invasive and uncomfortable and carries a small risk
of serious complications such as perforation [6]. In CGD,
information obtained from biopsy is of limited utility because
the chronic colitis disease process is similar in all patients and
acute infection can usually be diagnosed non-invasively.
Indeed, in this study, the pattern of inflammation seen on
biopsies (predominantly crypt architectural distortion,
cryptitis, and crypt abscess) was consistent between patients.
Although one patient on treatment but without evidence of
current colitis had evidence of mild crypt architectural distor-
tion and one had a granuloma (which presumably relates to the
underlying disease), such findings are unlikely to changeman-
agement decisions in the absence of visible colitis or elevated
fecal calprotectin. It is notable that in two bowel segments
(from one patient), acute changes were seen on histological
examination despite apparently normal colonoscopy and
Fig. 4 Utility of fecal calprotectin. a–d Comparison of disease activity
scores (endoscopic UCEIS score (a), MaRIA score (b), London score (c),
and CDMI score (d)) according to whether participants had normal or
elevated fecal calprotectin. Analysis is based on the total scores for the
entire colon (rectum to caecum) and p values are derived from t tests. e–h
Correlations between log(fecal calprotectin) and the disease activity
scores (endoscopic UCEIS score (a), MaRIA score (b), London score
(c), and CDMI score (d)). Analysis is based on the total scores for the
entire colon (rectum to caecum) and p values are derived from Pearson
correlation
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MRI, but this patient had clear endoscopic and radiological
evidence of colitis elsewhere and thus again these biopsies did
not alter the diagnosis. There were also four bowel segments
where histology was reported as normal despite unanimous
macroscopic and radiological evidence of colitis. We suggest
that this is likely to represent a sampling error, another poten-
tial issue with biopsy as it necessarily assesses only a small
portion of the bowel segment. In the absence of transverse
colon biopsies, we were unable to undertake a full correlation
between histological findings with the results of other
investigations.
Imaging techniques, including MRI, have been increasing-
ly demonstrated to be valuable in other inflammatory bowel
diseases [7, 8], and scoring systems have been developed [12,
13, 19]. We here demonstrated that MRI-derived scores of
colitis activity (BLondon^ score, MaRIA, and CDMI) corre-
lated well with colonoscopy scores (UCEIS). The correlation
between radiologists and with colonoscopy scores was best
for the London score, although all were highly significant.
Correlation between MRI scores and UCEIS was dem-
onstrated for each bowel segment assessed, albeit there
was no unanimous agreement between investigators or
modalities. MRI tended to overinterpret findings in the
rectum, especially in one patient with a prior history of
surgery and radiotherapy, suggesting poorer specificity in
this region as previously described [20]. Conversely, MRI
appeared somewhat less robust for detecting mild to mod-
erate colitis in the caecum. In all cases where there was
discordance, histological findings agreed with colonosco-
py supporting this as the gold standard.
Importantly, MRI scored higher than colonoscopy in
almost all questions relating to patient preference.
Despite a relatively small sample size, the difference in
scores was significant for pain, a desire to be less
awake, and taste of the bowel preparation drink.
Indeed, bowel preparation for colonoscopy scored partic-
ularly poorly and was unanimously rated as the worst
element in follow-up questionnaires. Of the nine follow-
up questionnaires received, six patients preferred MRI
over colonoscopy.
MRI was quicker than colonoscopy and was not asso-
ciated with adverse events (in contrast, one participant
suffered presumed bacterial translocation secondary to co-
lonoscopy). Furthermore, imaging was able to assess the
entire colon in all patients, while colonoscopy did not
reach the terminal ileum in three of ten participants and
in one patient only reached the splenic flexure. MRI addi-
tionally identified an undescended testis in one participant,
Fig. 5 Interleukin 12 level correlates with colitis activity. a–c
Correlations between serum interleukin 12 (IL-12) concentration and
the UCEIS score, MaRIA score, and London score. p values are derived
from Pearson correlation. d Serum IL-12 concentration according to
presence or absence of colitis. e Serum-soluble intercellular adhesion
molecule-1 (sICAM) concentration according to presence or absence of
immunosuppression (either moderate to high dose corticosteroids and/or
azathioprine). p value from unpaired t test
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while in a subsequent MRI scan assessing CGD colitis (not
included in the present study), we also identified pancreatic
abnormalities potentially consistent with intraductal papillary
mucinous neoplasm (IPMN).
As well as MRI, we also measured fecal calprotectin
in participants. Calprotectin, a dimer of the calcium-
binding proteins S100A8 and S100A9, is highly repre-
sented in neutrophils, and levels in feces are known to
reflect disease activity in other inflammatory bowel dis-
eases [21]. We found this to be an excellent discrimina-
tor of patients with and without colitis. Although there
were only 8 participants with a complete UCEIS score
and contemporaneous calprotectin, the remaining 2 pa-
tients appeared to maintain the same pattern (i.e., normal
FCP in a patient without evidence of colitis as far as the
splenic flexure (or more proximally on MRI) and elevat-
ed FCP in a subsequent sample from a patient who did
have macroscopic colitis). All patients with elevated
FCP had histological evidence of colitis, whereas those
with normal FCP had either normal histology or chronic
quiescent changes only. The FCP result, especially when
log-transformed, correlated well with colitis activity. Of
note, log(fecal calprotectin) correlated with colitis activ-
ity much better than serum C-reactive protein (whether
or not log-transformed): this is likely to reflect the fact
that patients with CGD can have many other causes of
systemic inflammation and concurs with another recent
study [10].
Consistent with this conclusion, many serum cytokine
levels did not show clear correlations with colitis activity:
for example, one participant had very high levels of innate
cytokines despite the absence of active colitis. However,
IL-12 concentration did correlate with most measures of
disease activity. Successful treatment of CGD colitis with
the IL-12/23 inhibitor ustekinumab has been described
[22], and if our results are replicated in larger cohorts
and in studies of gene expression at the disease site, then
this treatment target should certainly be further explored.
IL-12 may also be useful for disease monitoring, and fur-
ther prospective studies—perhaps correlating with disease
activity as assessed by serial MRI and FCP—would help
to clarify this.
The apparent negative correlation between disease ac-
tivity and serum ICAM-1 levels appeared to be explained
by the impact of immunosuppression. This result may
nevertheless be important as it suggests that patients with
CGD, even in the absence of colitis, may have evidence of
endothelial activation with the attendant risk of vascular
complications [23]. Regardless of the impact on colitis,
broad-spectrum immunosuppression may at least amelio-
rate this risk. Again, this finding requires further confir-
mation in a larger group, but a cardiovascular risk pheno-
type in other chronic inflammatory disorders is well
recognized [23] and may become an important source of
morbidity in older CGD patients.
Our clinical score based on the Harvey-Bradshaw in-
dex did not perform well in predicting colitis activity.
There appear to be several explanations for this.
BGeneral wellbeing^ in CGD may be impacted upon
by more than just colitis due to the multisystem nature
of the disorder. Interestingly, pain was not a dominant
feature, only reported by three patients and never se-
vere. Finally, one participant reported frequent liquid
stools despite having normal endoscopic and MRI find-
ings: excluding this participant did result in weak sig-
nificant correlations (maximal R2 0.50) with MRI scores
and approaching significant correlation with UCEIS (R2
0.50, p = 0.06).
Our study had some limitations, most notably the rela-
tively small number of participants. This was of especial
importance for cytokine measurements: for example, one
patient with significant colitis activity had unusually low
results for all measured cytokines which markedly weak-
ened the observed correlations. However, CGD is a rare
disorder and, after exclusions, there was a limited potential
pool of participants; most patients who declined participa-
tion had no symptoms of colitis and would not have had a
clinical indication for colonoscopy. Some participants were
already on treatment for colitis which would likely have
affected endoscopic, MRI, and serum findings, but due to
available numbers, it was not possible to restrict the study
to patients who were treatment naïve. The study was per-
formed at a tertiary referral center with MRI scans reported
by specialist radiologists. This may limit extrapolation to
all settings, although CGD patients are usually cared for in
specialized services.
In summary, we have demonstrated that CGD-
associated colitis can be assessed non-invasively. Fecal
calprotectin can be used to confidently exclude active co-
litis if normal, and the level will give an indication of
disease activity. Serum interleukin-12 concentration may
also correlate with disease activity and points towards a
targeted treatment. Although it may still be important to
perform colonoscopy to confirm a diagnosis, and intermit-
tently thereafter, MRI imaging can be used for some mon-
itoring of disease activity. It will be of particular benefit
for those unable to tolerate or with contraindications to
colonoscopy. While its use in children may be affected
by the need for sedation and requirement to ingest a rela-
tively unpalatable drink, these issues equally apply to co-
lonoscopy. In adults, this modality is better tolerated and
generally preferred by patients, is quicker, is safer, is more
likely to visualize the entire large bowel to terminal ileum,
and can identify additional pathologies outside the gastro-
intestinal tract. We recommend that it is incorporated into
routine clinical practice.
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